About Alliqua BioMedical
Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company's businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company's commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers TheraBond 3D Antimicrobial Barrier Systems and SilverSeal.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ALQA
- Previous Close: $0.48
- 50 Day Moving Average: $0.578
- 200 Day Moving Average: $0.741
- 52-Week Range: $0.45 - $1.48
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.72
- P/E Growth: -0.040
- Market Cap: $14.36M
- Outstanding Shares: 29,672,000
- Beta: 1.15
- Net Margins: -81.72%
- Return on Equity: -52.26%
- Return on Assets: -33.50%
Companies Related to Alliqua BioMedical:
- Current Ratio: 0.91%
- Quick Ratio: 0.74%
What is Alliqua BioMedical's stock symbol?
Alliqua BioMedical trades on the NASDAQ under the ticker symbol "ALQA."
Where is Alliqua BioMedical's stock going? Where will Alliqua BioMedical's stock price be in 2017?
5 brokerages have issued 12-month price targets for Alliqua BioMedical's shares. Their predictions range from $2.50 to $3.00. On average, they anticipate Alliqua BioMedical's share price to reach $2.88 in the next year.
When will Alliqua BioMedical announce their earnings?
Alliqua BioMedical is scheduled to release their next quarterly earnings announcement on Wednesday, February, 22nd 2017.
Who owns Alliqua BioMedical stock?
Alliqua BioMedical's stock is owned by many different of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (6.48%), J. Goldman & Co LP (1.82%) and Renaissance Technologies LLC (1.38%). Company insiders that own Alliqua BioMedical stock include Bradford Barton, Brian M Posner, Corp /De/ Celgene, David Ian Johnson, Jerome B Zeldis and Pellegrino Pionati.
Who bought Alliqua BioMedical stock? Who is buying Alliqua BioMedical stock?
Alliqua BioMedical's stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC and Renaissance Technologies LLC. Company insiders that have bought Alliqua BioMedical stock in the last two years include Bradford Barton, Brian M Posner, Corp /De/ Celgene, David Ian Johnson, Jerome B Zeldis and Pellegrino Pionati.
How do I buy Alliqua BioMedical stock?
Shares of Alliqua BioMedical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Alliqua BioMedical stock cost?
One share of Alliqua BioMedical stock can currently be purchased for approximately $0.48.